{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:45:57Z","timestamp":1785239157281,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-00978-z","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T01:02:27Z","timestamp":1705366947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 2023;13:160.","journal-title":"Blood Cancer J"},{"key":"978_CR2","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569\u201375.","journal-title":"Blood"},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"978_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","volume":"5","author":"EM Hurt","year":"2004","unstructured":"Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5:191\u20139.","journal-title":"Cancer Cell"},{"key":"978_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"978_CR6","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","volume":"35","author":"J Croft","year":"2021","unstructured":"Croft J, Ellis S, Sherborne AL, Sharp K, Price A, Jenner MW, et al. Copy number evolution and its relationship with patient outcome\u2014an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2021;35:2043\u201353.","journal-title":"Leukemia"},{"key":"978_CR7","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1097\/HS9.0000000000000831","volume":"7","author":"A Panopoulou","year":"2023","unstructured":"Panopoulou A, Easdale S, Ethell M, Nicholson E, Potter M, Giotas A, et al. Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients. Hemasphere. 2023;7:e831.","journal-title":"Hemasphere"},{"key":"978_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl J Med. 2014;371:906\u201317.","journal-title":"N. Engl J Med"},{"key":"978_CR9","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2021;40:2901\u201312.","journal-title":"J Clin Oncol"},{"key":"978_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24:64\u201376.","journal-title":"Lancet Oncol"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the Harmony project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00978-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:02:23Z","timestamp":1705410143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00978-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-00978-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HM: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi, Amgen, Takeda; Research funding Janssen. MK: Honoraria: Janssen, Takeda, AbbVie, Sanofi; Consulting or advisory role: AbbVie, GSK, Janssen, Pfizer, Seattle Genetics, Takeda; Research funding: BMS\/Celgene (to institution), Janssen (to institution). RF: Consulting: AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; Scientific Advisory Boards: Adaptive Biotechnologies, Caris Life Sciences, Oncotracker.; Board of Directors<b>:<\/b> Antegene (for profit), AZBio (not for Profit); Patent for FISH in MM - ~$2000\/year.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}